Navigation Links
Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
Date:12/11/2012

n spread to other tissues, such as bone marrow and liver. In the United States, there are approximately 70,130 new cases of NHL and 4,600 new cases of MCL each year.

About Ibrutinib

Ibrutinib was designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK). BTK is a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel – regulating B-cell apoptosis, cell adhesion, and lymphocyte migration and homing. Through these multiple actions, BTK helps to direct malignant B cells to lymphoid tissues, thus allowing access to a microenvironment necessary for survival.

The effectiveness of ibrutinib alone or in combination with other treatments is being studied in several B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic lymphoma, relapsed/refractory mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma and multiple myeloma. The clinical development program includes 23 clinical trials – six Phase 3, nine Phase 2, one Phase 1/2, and seven Phase 1 trials currently underway.

About the Janssen and Pharmacyclics Collaboration

Janssen Biotech, Inc. and Pharmacyclics Inc. entered into a worldwide collaboration on December 8, 2011, to develop and commercialize ibrutinib. Following regulatory approval, Janssen and Pharmacyclics will co-commercialize ibrutinib. In the United States, both companies will share in commercialization activities; outside the United States, Janssen will lead and perform commercialization activities. Each company is leading development for specific indications.

About Janssen Research & Development, LLC

Janssen Research & Development, LLC is headquartered in Raritan, N.J. and has affiliated facilities in Europe, the United States and Asia. Janssen Research & Development is leveraging a combination of internal and external innovation to discover and develop novel
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
2. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
3. Landauer, Inc. Reports Fiscal 2012 Fourth Quarter And Year End Results
4. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
5. IRIDEX Corporation Announces Preliminary Results of its Tender Offer
6. American Pacific to Release Financial Results and Hold Fiscal 2012 Year-End and Fourth Quarter Investor Teleconference
7. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
8. The Female Health Company Reports Record Fourth Quarter and FY2012 Operating Results
9. ObeTherapy Announces the Publication of Results Obtained with one of its Lead Compounds on a New Target for the Treatment of Obesity and Type II Diabetes
10. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
11. Landauer, Inc. Sets Date And Time For Announcement Of Fiscal Fourth Quarter And Full Year 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... UBM Medica US announces that Neurology Times ... for neurologists and other healthcare providers, features special coverage on ... discussions of the latest developments in approaches to diagnosis. ... , more than the total of those who have multiple ... can be difficult because there are no confirmatory medical tests. ...
(Date:10/17/2014)... -- A victim of medical negligence at the hands of ... history of alcohol abuse, a physician and consumer advocates unveiled ... highlighting how Prop 46 will identify and deter physician substance ... The ad pictures a doctor drinking at a bar as ... will enact the first law in the nation requiring random ...
(Date:10/17/2014)... InnFocus, Inc ., reported on results of 59 glaucoma patients ... up to 3 years with the InnFocus MicroShunt® at the ... . The Summit was held ... American Academy of Ophthalmology . The Company also said ... 6 countries by early 2015. Logo - ...
Breaking Medicine Technology:Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 2Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 4InnFocus Featured at the Ophthalmology Innovation Summit In Chicago 2
... June 1, 2010 MediSapiens, world,s first,software company for personalized cancer ... ( EUR 0.8 million ) seed round,investment from Veraventure, ETFIII advised by ... , , ... at the VTT Technical Research,Centre of Finland and its collaborators. ...
... TEL AVIV, Israel , May 31, 2010 ... for the first,quarter of 2010. , , ... Loss for the first quarter of 2010 attributable to the ... minority interest,totaled to NIS 170 million ), as compared to gain attributable ...
Cached Medicine Technology:MediSapiens Gets $ 1 Million for World's First Personalized Cancer Medicine Software 2MediSapiens Gets $ 1 Million for World's First Personalized Cancer Medicine Software 3MediSapiens Gets $ 1 Million for World's First Personalized Cancer Medicine Software 4Elbit Imaging Ltd. Announces First Quarter Results for 2010 2Elbit Imaging Ltd. Announces First Quarter Results for 2010 3Elbit Imaging Ltd. Announces First Quarter Results for 2010 4Elbit Imaging Ltd. Announces First Quarter Results for 2010 5Elbit Imaging Ltd. Announces First Quarter Results for 2010 6Elbit Imaging Ltd. Announces First Quarter Results for 2010 7Elbit Imaging Ltd. Announces First Quarter Results for 2010 8Elbit Imaging Ltd. Announces First Quarter Results for 2010 9Elbit Imaging Ltd. Announces First Quarter Results for 2010 10Elbit Imaging Ltd. Announces First Quarter Results for 2010 11Elbit Imaging Ltd. Announces First Quarter Results for 2010 12
(Date:10/20/2014)... JZ Fitness, an independently operated wellness ... programming, authorship, international lecturing and community wellness, created by ... release of the JZ Fitness nutrition app, available on ... thousands of individuals on nutrition, Jenn Zerling (“JZ”) has ... require calorie counting or cumbersome food logging. ...
(Date:10/20/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Sit and Slim II . ... purchase or use Sit and Slim II because it contains ... promoted as weight loss product on various websites and possibly ... in 2010 for safety reasons, can significantly increase blood pressure ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked in ... Every Body Walk! campaign by Kaiser Permanente. ... workers to be more active outside of the workplace. ... the end of September, was a friendly competition between organizations ... Participating companies gave their staff pedometers and each day, for ...
(Date:10/20/2014)... Viejo, California (PRWEB) October 20, 2014 Final ... announced the release of the Citrus theme for FCPX ... I would use to describe the Citrus theme” Says Christina ... so easy to look so professional.” , Citrus comes with ... Included with the template are: four transitions for added style, ...
(Date:10/20/2014)... 2014 Punzoné , the first line ... has a lot to celebrate this month. October marks Italian ... achievements and contributions of Americans of Italian heritage and Italians ... today it shares its favorite Italian cocktails and encourages everyone ... - even if it is only in a glass. ...
Breaking Medicine News(10 mins):Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4
... FL (April 6, 2011) Breast cancer is the second ... diagnosed each year. Being exposed to estrogen over a long ... woman,s risk of developing the disease. One way a ... breast cancer drug tamoxifen, which interferes with the activity of ...
... Gardner HealthDay Reporter , TUESDAY, April 5 ... impaired glucose tolerance seem to fare equally well when ... suggests. Although an angiotensin II receptor blocker (ARB) ... this patient population, one difference did emerge, according to ...
... Eating strawberries may be a way to help people at ... to a new study by researchers at The Ohio State ... and Richard J. Solove Research Institute (OSUCCC James) and ... findings during a press briefing at 8 a.m. April 6 ...
... News) -- Babies born to mothers who were obese in early ... up to one year after birth, a new British study says. ... at five maternity units in northern England from 2003 to 2005. ... death) or up to one year after birth (infant death) was ...
... An editorial in the April 6 issue of the ... hormone therapy in women who have had a hysterectomy because ... cancer. The editorial is a response to a study ... estrogen-only therapy, currently used in women with menopausal symptoms who ...
... TUESDAY, April 5 (HealthDay News) -- Over the last two decades ... are now at a record low, government health officials report. ... still up to nine times that of other affluent nations, and ... in 2009 alone, according to the U.S. Centers for Disease Control ...
Cached Medicine News:Health News:Fox Chase researchers find that fish oil boosts responses to breast cancer drug tamoxifen 2Health News:Two Different Heart Drugs May Work Equally Well for High-Risk Patients 2Health News:Two Different Heart Drugs May Work Equally Well for High-Risk Patients 3Health News:An international study in China finds strawberries may slow precancerous growth in the esophagus 2Health News:An international study in China finds strawberries may slow precancerous growth in the esophagus 3Health News:Babies Born to Obese Moms Face Higher Death Risk: Study 2Health News:Caution for estrogen therapy after hysterectomy 2Health News:Caution for estrogen therapy after hysterectomy 3Health News:U.S. Teen Birth Rate Hits Record Low 2Health News:U.S. Teen Birth Rate Hits Record Low 3Health News:U.S. Teen Birth Rate Hits Record Low 4
3.2 mm Keratome, double bevel, sharp sides, ang. 1 Ea as quantity....
... 50Hz/60Hz is the most powerful isolated ESU on ... Coag. It is the only ESU that allows ... surgical field with a standard ES pencil. Excalibur ... maintains minimum necessary voltage for smooth cutting through ...
Microcontroller-based isolated electrosurgical generator, designed for all general purpose surgical procedures. Unit includes: Instant Response technology, adaptive REM system, isolated output, CEM c...
Lorgnette pinhole occluder...
Medicine Products: